<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=234748540252369&amp;ev=PageView&amp;noscript=1">

Diopsys Insights

Diopsys Turns 20!

Posted by Diopsys, Inc. on September 22, 2018 at 3:29 PM


The Evolution of Objective, Functional Testing in Ophthalmic Practices

INTRODUCTION:

Twenty years ago, visual electrophysiology testing was not widely used in the eye care office, and its importance to routine clinical practice was poorly understood. Diopsys has changed all that.

The early experience with visual electrophysiology is hardly reflective of how this testing is used in modern eye care today, especially with the advent of smaller platforms and streamlined protocols. Even as new diagnostic technology has entered the eye care space, electrophysiology testing has gained a more prominent role in evaluating patients, precisely because no other testing modality can deliver both objective and functional information about the health of retinal cells. For eye care specialists, that kind of data is indispensable for deciding who to treat and how to treat.

“It's another tool in the toolbox,” said Mark Latina, MD, “We think we understand a lot of diseases, we think we know what we are doing, but this testing gives us an objective functional approach to patients, and that is a huge benefit.”

Read More

Topics: Visual Electrophysiology

Light Induced Visual-response (LIV)

Introduction:

Light Induced Visual-response (LIV) measures the electrical responses of cells within the eye upon stimulation by a light source. Various stimuli can be used to target different cells within the visual pathway to gain objective information regarding their function, thus allowing clinicians to detect even subtle changes in cell health and viability. But what is the real value of LIV?

With objective, functional data, Light Induced Visual-response allows for tailored treatment and more precise disease management.

Read More

Topics: Visual Electrophysiology

This is Why You Need Multifocal ERG if You Have Plaquenil Patients

Posted by Diopsys, Inc. on May 2, 2018 at 4:59 PM

Testing for Chloroquine and Hydroxychloroquine Retinopathy

Introduction:
Although the exact mechanism by which chloroquine (CQ) and hydroxychloroquine (HCQ - commonly known as Plaquenil) induce retinal toxicity is not well understood, but it is recognized as a serious ophthalmologic concern because it is not treatable.1 Guidelines from the American Academy of Ophthalmology (AAO) on screening for CQ and HCQ toxicity recommend that all patients starting therapy receive a baseline screening followed by annual follow-up visits beginning at 5 years after the start therapy—although some individuals with certain high risk factors might require closer monitoring.1 Above and beyond their role in screening, eye care professionals have a valuable role in educating patients and medical colleagues about safe dosing, risk factors, and the need for screening.

Read More

Topics: Multifocal ERG

Ophthalmology Spotlight: How Patients Benefit from ERG Vision Testing

Posted by Diopsys, Inc. on March 29, 2018 at 8:49 AM

An Interview with William I. Bond, MD, FACS:

After over 40 years in practice, William I. Bond, MD has gotten fairly confident in his ability to evaluate a patient in the clinic and understand the health of the eye. 

The kind of knowledge that only comes from interacting with patients of all ages and vision disorders daily is a valuable tool when working with a new vision loss patient. It is what helps Dr. Bond look at a patient with a cataract, for example, and have an awareness that something else might be going on, perhaps something unseen that is affecting one or more parts of the complex human visual system. It may be that the degree of refractive change a patient is experiencing is more profound than what is suggested by the stage of the cataract. Yet, what that “something else” might be is not always obvious.

Read More

Topics: Pattern ERG, Flicker ERG

Retina Focus: How Do You Know if Treatment is Working?

Posted by William Ayliffe, FRCS, PHD on March 5, 2018 at 3:43 PM

The utility of objective, quantitative metrics for making treatment decisions.

INTRODUCTION:

Determining the effectiveness of treatment in a patient with suspected retinal pathology can be challenging. While visual acuity can serve as a benchmark, vision gains do not necessarily correlate with improvement in structure or global function. Despite the array of diagnostic modalities available to the eye care expert, very few of them deliver actionable information that is helpful in deciding if treatment is working, when to change course, or perhaps even when to cease treatment because risks outweigh the potential benefits.

Read More

Topics: Flicker ERG

Diabetic Retinopathy Management: An Advanced Approach

Posted by Alberto González García, M.D., Chief Medical Officer, Diopsys on February 1, 2018 at 9:43 AM

INTRODUCTION:

Patients with diabetic retinopathy can present difficult clinical questions, even to the most experienced experts. Whether and when to administer treatment and how to gauge effectiveness are topics that have been front and center in eye care for a long time. More fundamentally, understanding precisely how the disease is affecting the health of the eye has proven challenging, because while measurements like vision loss signify disease progression, visual acuity recovery after treatment does not necessarily correlate with improvement in underlying structure and function.

Read More

Topics: Flicker ERG, Diabetic Retinopathy

The Reason This Ophthalmologist Uses Flicker ERG

Posted by Mitchell A. Jackson, M.D. on December 9, 2016 at 3:09 AM

INTRODUCTION:

All of us anterior segment surgeons have coached our patients through the cataract surgery procedure and what type of vision they can expect when fully healed. The potential for diagnosing an existing retinopathy in patients with mild cataracts prior to surgery is relatively high. But predicting retinopathies and setting the proper patient expectations become more difficult when a dense cataract prohibits me from getting a reliable OCT or fundus photo. So what do I tell these patients? 

Now I have a reliable, objective test of retinal function that I can perform pre-operatively to give me an idea of what's going on behind the cataract. Flicker ERG has helped me ensure that these patients are accurately prepared for the outcome of their surgery. 

Read More

Topics: Flicker ERG

Glaucoma and ERG:
What I Knew vs. What I Now Know

Posted by Robert J. Noecker, MD, MBA on October 13, 2016 at 12:43 PM

My interest in glaucoma diagnostic devices started early in my career during a Fellowship at Tufts, and has only increased with time. I’ve held positions as Director of Glaucoma at UPMC and the University of Arizona School of Medicine, and as a faculty member at Yale University School of Medicine. You could say I’m infinitely curious about how to detect the disease earlier, treat the disease more effectively, and manage my patients to maintain their ability to see. So when I was introduced to pattern electroretinography (ERG) as a practice-based vision test, my curiosity took over. Here’s what I knew from my previous experience:

Read More

Topics: Glaucoma, Pattern ERG

What do I see on this VEP?
A Quick Waveform Review

Posted by Diopsys, Inc. on September 28, 2016 at 4:00 PM

INTRODUCTION:

Visual Evoked Potential (VEP) has been used for over 50 years in the clinical management of patients with a variety of vision problems. It was not until the last 10 years, however, that visual electrophysiology devices were made consistently available to the office-based eye care professional.

VEP test results give ophthalmologists and optometrists objective, functional information about the entire vision system. These test results often have a few components. Here is a quick review of the most important section: the pattern-reversal VEP waveform.

Read More

Topics: Visual Evoked Potential (VEP)

Diopsys, Inc: Our ERG and VEP History

Posted by Diopsys, Inc. on September 28, 2016 at 3:21 PM

INTRODUCTION:

Diopsys introduced its first visual evoked potential (VEP) device at the American Academy of Pediatrics meeting in 2004, and has been leading the visual electrophysiology space ever since. Our Research and Development program is very important to the success of our vision testing devices, and our customers have benefited from our continuous product expansions. In addition to all of the clinical research done in the last 16 years, we currently have 15 studies running at several prestigious institutions, such as:

  • Wills Eye Hospital
  • Doheny Eye Institute
  • New York Eye and Ear Infirmary
  • University of Pittsburgh Medical Center (UPMC)
  • UCSF Medical Center

Take a look at our brief history below to see where we came from, and where we're headed.

Read More

Topics: Visual Electrophysiology

Modern Visual Electrophysiology

World Leading Technology

As the world leader in modern visual electrophysiology, Diopsys, Inc. has done more than any other company to advance the use of ERG and VEP in the eye care practice. Read through our blog to gain valuable insights into the benefits and integration of this valuable technology.

Subscribe to Email Updates

Recent Posts